Chinese American Biopharmaceutical Society Serves As Bridge For China Talent, U.S. Execs
This article was originally published in PharmAsia News
Chinese American Biopharmaceutical Society president and president-elect discuss how their organization can help bridge China’s talent gap as many of their members return to China.
You may also be interested in...
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
Pfizer Inc.’s latest pledge to academic research, a five-year $85 million agreement to fund projects at the University of California, San Francisco, isn’t just a deepening of the Big Pharma’s commitment to on-campus studies intended to bridge the so-called Valley of Death between the laboratory and the commercial sector. It’s also a sign of the increased importance of deals between pharmas and universities, which give commercial partners access to new research earlier in the development process while nudging academics toward projects with commercial relevance in mind.
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.